Enhancing PSMA-PET/CT with intravenous contrast: Improved tracer clearance in the prostate bed.

IF 1 4区 医学 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Nuklearmedizin-nuclear Medicine Pub Date : 2022-06-14 DOI:10.1055/a-1821-8112
A. Tulipan, Angela Jaramillo Guzman, T. Haslerud, Kjartan Foldnes, O. Kvernenes, A. Honoré, N. Brekke, L. Reisæter, M. Biermann
{"title":"Enhancing PSMA-PET/CT with intravenous contrast: Improved tracer clearance in the prostate bed.","authors":"A. Tulipan, Angela Jaramillo Guzman, T. Haslerud, Kjartan Foldnes, O. Kvernenes, A. Honoré, N. Brekke, L. Reisæter, M. Biermann","doi":"10.1055/a-1821-8112","DOIUrl":null,"url":null,"abstract":"AIMS\nWe observed hitherto unreported layering of radioactivity in the bladder on PET/CT in prostate cancer (PC) when combined with contrast-enhanced CT (CECT). This effect facilitates assessment of the prostate bed in PC.\n\n\nMETHODS\nAmong 128 patients imaged with [18F]PSMA-1007, we selected all 8 studies without and 28 studies with CECT. 20 patients also underwent PET/MR. As controls, we chose 20 and 16 males studied with [18F]FDG for extrapelvic disease with and without CECT. Posterior anterior (PA) ratio was calculated as SUVpost/SUVant * 100 % based on maximal standard uptake values (SUV) in 20 mm spheres in the anterior and posterior bladder. Four nuclear physicians scored assessibility of the bladder base on a 3-point Likert scale (3 = optimal, 1 = poor). We acquired serial PET/CT over 4 hours of a flask with layering of 100 ml intravenous contrast agent and 100 ml physiological saline with 40 MBq of [18F]PSMA-1007, while a control flask was shaken at the start of the experiment.\n\n\nRESULTS\nLayering of tracer was observed in all PET/CT studies with CE-CT, but not in studies without contrast. Median PA ratios were 44 % (interquartile range 33-62) for [18F]PSMA-1007 and 73 % (52-67) for [18F]FDG, respectively. Intravenous contrast improved assessibility scores in PET of the bladder base, but the effect only reached significance in the PET/MR data. In the in vitro data, radioactivity was retained in the aqueous supernatant over the entire experiment whereas there was no separation of phases in the control flask over time.\n\n\nCONCLUSION\nWhen performing PET combined with CECT, sedimentation of contrast agent in the bladder leads to upward displacement of radioactivity, enhancing clarity of PET images in the posterior bladder and the prostate bed on both PET/CT and PET/MR.","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":1.0000,"publicationDate":"2022-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nuklearmedizin-nuclear Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1055/a-1821-8112","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 2

Abstract

AIMS We observed hitherto unreported layering of radioactivity in the bladder on PET/CT in prostate cancer (PC) when combined with contrast-enhanced CT (CECT). This effect facilitates assessment of the prostate bed in PC. METHODS Among 128 patients imaged with [18F]PSMA-1007, we selected all 8 studies without and 28 studies with CECT. 20 patients also underwent PET/MR. As controls, we chose 20 and 16 males studied with [18F]FDG for extrapelvic disease with and without CECT. Posterior anterior (PA) ratio was calculated as SUVpost/SUVant * 100 % based on maximal standard uptake values (SUV) in 20 mm spheres in the anterior and posterior bladder. Four nuclear physicians scored assessibility of the bladder base on a 3-point Likert scale (3 = optimal, 1 = poor). We acquired serial PET/CT over 4 hours of a flask with layering of 100 ml intravenous contrast agent and 100 ml physiological saline with 40 MBq of [18F]PSMA-1007, while a control flask was shaken at the start of the experiment. RESULTS Layering of tracer was observed in all PET/CT studies with CE-CT, but not in studies without contrast. Median PA ratios were 44 % (interquartile range 33-62) for [18F]PSMA-1007 and 73 % (52-67) for [18F]FDG, respectively. Intravenous contrast improved assessibility scores in PET of the bladder base, but the effect only reached significance in the PET/MR data. In the in vitro data, radioactivity was retained in the aqueous supernatant over the entire experiment whereas there was no separation of phases in the control flask over time. CONCLUSION When performing PET combined with CECT, sedimentation of contrast agent in the bladder leads to upward displacement of radioactivity, enhancing clarity of PET images in the posterior bladder and the prostate bed on both PET/CT and PET/MR.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
增强PSMA-PET/CT静脉造影剂:改善前列腺床示踪剂清除率。
目的:我们在前列腺癌(PC)的PET/CT上观察到迄今未报道的膀胱放射性分层,当结合对比增强CT (CECT)时。这一效应有助于评估前列腺癌患者的前列腺床。方法在128例经[18F]PSMA-1007显像的患者中,我们选择了8例未行CECT的研究和28例行CECT的研究。20例患者同时接受PET/MR检查。作为对照,我们选择了20名和16名男性[18F]FDG研究盆腔外疾病伴和不伴CECT。根据前膀胱和后膀胱20 mm球的最大标准摄取值(SUV)计算后前(PA)比为SUVpost/SUVant * 100%。4名核内科医生对膀胱基底的可评估性进行3分李克特评分(3 =最佳,1 =差)。我们在4小时的时间里对一个烧瓶进行了连续PET/CT扫描,烧瓶中分别滴入100毫升静脉造影剂和100毫升生理盐水,并加入40 MBq的[18F]PSMA-1007,同时在实验开始时摇晃一个对照烧瓶。结果在所有PET/CT联合CE-CT的研究中都观察到示踪剂的消失,而在没有对比的研究中则没有。[18F]PSMA-1007和[18F]FDG的中位PA比率分别为44%(四分位数范围33-62)和73%(52-67)。静脉造影剂提高了膀胱基底PET的可评估性评分,但仅在PET/MR数据中达到显著效果。在体外实验数据中,放射性在整个实验过程中都保留在水上清液中,而在对照烧瓶中,随着时间的推移没有相分离。结论PET与CECT联合应用时,造影剂在膀胱内的沉降导致放射性向上移位,增强了PET/CT和PET/MR上后膀胱和前列腺床的PET图像清晰度。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
1.70
自引率
13.30%
发文量
267
审稿时长
>12 weeks
期刊介绍: Als Standes- und Fachorgan (Organ von Deutscher Gesellschaft für Nuklearmedizin (DGN), Österreichischer Gesellschaft für Nuklearmedizin und Molekulare Bildgebung (ÖGN), Schweizerischer Gesellschaft für Nuklearmedizin (SGNM, SSNM)) von hohem wissenschaftlichen Anspruch befasst sich die CME-zertifizierte Nuklearmedizin/ NuclearMedicine mit Diagnostik und Therapie in der Nuklearmedizin und dem Strahlenschutz: Originalien, Übersichtsarbeiten, Referate und Kongressberichte stellen aktuelle Themen der Diagnose und Therapie dar. Ausführliche Berichte aus den DGN-Arbeitskreisen, Nachrichten aus Forschung und Industrie sowie Beschreibungen innovativer technischer Geräte, Einrichtungen und Systeme runden das Konzept ab. Die Abstracts der Jahrestagungen dreier europäischer Fachgesellschaften sind Bestandteil der Kongressausgaben. Nuklearmedizin erscheint regelmäßig mit sechs Ausgaben pro Jahr und richtet sich vor allem an Nuklearmediziner, Radiologen, Strahlentherapeuten, Medizinphysiker und Radiopharmazeuten.
期刊最新文献
The Medical Informatics Initiative and the Network University Medicine - Perspectives for Nuclear Medicine. Combined morphologic-metabolic biomarkers from [18F]FDG-PET/CT stratify prognostic groups in low-risk NSCLC. NuklearMedizin 2024: Abstract-Einreichung bis zum 1. November geöffnet! DGN-Forschungs- und -Förderpreise Preisverleihungen
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1